Lithium for Low-Grade Neuroendocrine Tumors

PHASE2CompletedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

July 31, 2007

Primary Completion Date

June 30, 2009

Study Completion Date

June 30, 2009

Conditions
Neuroendocrine Tumors
Interventions
DRUG

Lithium Carbonate

Lithium 300mg PO TID escalating to a lithium level of 0.8-1.2. Lithium carbonate will be administered the first week at 300 mg flat dose three times each day. A serum lithium level will be checked after 4-5 days of treatment by drawing a blood sample prior to the morning dose of lithium. Evaluate every 8 weeks.

Trial Locations (1)

53792

University of Wisconsin Paul P. Carbone Comprehensive Cancer Center, Madison

All Listed Sponsors
collaborator

National Institutes of Health (NIH)

NIH

collaborator

National Cancer Institute (NCI)

NIH

lead

University of Wisconsin, Madison

OTHER

NCT00501540 - Lithium for Low-Grade Neuroendocrine Tumors | Biotech Hunter | Biotech Hunter